Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 5
Submit an article Journal homepage
540
Views
48
CrossRef citations to date
0
Altmetric
Original Article: Clinical

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

Oliver Weigert Department of Internal Medicine III, University of Munich, Munich, GermanyCorrespondence[email protected]
, MD,
Eckhart Weidmann Department of Internal Medicine II, Hospital Nordwest, Frankfurt, Germany
,
Rudolf Mueck Department of Internal Medicine II, Diakonie Hospital, Stuttgart, Germany
,
Martin Bentz Department of Internal Medicine II, Hospital of Karlsruhe, Karlsruhe, Germany
,
Christoph von Schilling Department of Internal Medicine III, Hospital of Freising, Technical University of Munich, Munich, Germany
,
Robert Rohrberg Clinic for Hematology/Oncology, Halle, Germany
,
Kathleen Jentsch-Ullrich Department of Internal Medicine, University of Magdeburg, Magdeburg, Germany
,
Wolfgang Hiddemann Department of Internal Medicine III, University of Munich, Munich, Germany
&
Martin Dreyling Department of Internal Medicine III, University of Munich, Munich, Germany
 show all
Pages 716-722 | Received 21 Nov 2008, Accepted 28 Feb 2009, Published online: 21 Jul 2009

Citations (48)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Tadeusz Robak, Piotr Smolewski, Pawel Robak & Martin Dreyling. (2019) Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Leukemia & Lymphoma 60:11, pages 2622-2634.
Read now
Richard Arkwright, Tri Minh Pham, Jeffrey A. Zonder & Q. Ping Dou. (2017) The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Drug Discovery 12:2, pages 225-235.
Read now
Danyu Sun & Mitchell R Smith. (2014) Bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Orphan Drugs 2:11, pages 1233-1241.
Read now
Andre Goy. (2013) Mantle cell lymphoma: continuously improving the odds!. Expert Opinion on Orphan Drugs 1:12, pages 1001-1018.
Read now
Jeanette K Doorduijn & Hanneke C Kluin-Nelemans. (2013) Management of mantle cell lymphoma in the elderly patient. Clinical Interventions in Aging 8, pages 1229-1236.
Read now
Valérie Camara-Clayette, Olivier Hermine & Vincent Ribrag. (2012) Emerging agents for the treatment of mantle cell lymphoma. Expert Review of Anticancer Therapy 12:9, pages 1205-1215.
Read now
Simon Rule. (2011) Velcade combinations in mantle cell lymphoma: are we learning anything?. Leukemia & Lymphoma 52:4, pages 545-547.
Read now
C. Tom Kouroukis, Louis A. V. Fernandez, Michael Crump, Neil Sun Chua, Rena Buckstein, Robert Turner, Sarit Assouline, Richard J. Klasa, Wendy Walsh, Jean Powers & Elizabeth Eisenhauer. (2011) A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukemia & Lymphoma 52:3, pages 394-399.
Read now
Bhupender S Chhikara & Keykavous Parang. (2010) Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7:12, pages 1399-1414.
Read now
Oliver Weigert, Michael Unterhalt, Wolfgang Hiddemann & Martin Dreyling. (2009) Mantle cell lymphoma: state-of-the-art management and future perspective. Leukemia & Lymphoma 50:12, pages 1937-1970.
Read now

Articles from other publishers (38)

Junghoon Shin, Ji Yun Lee, Gyeong‐Won Lee, Won Seog Kim, Yong Park, Young Rok Do, Dae Sik Kim, Ki Hwan Kim, Yoon Seok Choi, Ja Min Byun, Junshik Hong, Inho Kim, Sung‐Soo Yoon & Youngil Koh. (2023) Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma . British Journal of Haematology.
Crossref
Elisabeth Silkenstedt, Kim Linton & Martin Dreyling. (2021) Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches. British Journal of Haematology 195:2, pages 162-173.
Crossref
Elisabeth Silkenstedt, Martin Dreyling & Simon Rule. 2021. Indolent Lymphomas. Indolent Lymphomas 163 178 .
G.R. Tundo, D. Sbardella, A.M. Santoro, A. Coletta, F. Oddone, G. Grasso, D. Milardi, P.M. Lacal, S. Marini, R. Purrello, G. Graziani & M. Coletta. (2020) The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacology & Therapeutics 213, pages 107579.
Crossref
Pawel Robak & Tadeusz Robak. (2019) Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs in R&D 19:2, pages 73-92.
Crossref
Yun Liu, Wen-Jing Huang, Min-Ting Lin, Jia-Jun Li & Jian-Ye Zhang. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy 207 228 .
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman & Sara Ek. (2018) Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. BMC Cancer 18:1.
Crossref
Pamela McKay, Mike Leach, Bob Jackson, Stephen Robinson & Simon Rule. (2018) Guideline for the management of mantle cell lymphoma. British Journal of Haematology 182:1, pages 46-62.
Crossref
Christian W. Eskelund, Christina Dahl, Jakob W. Hansen, Maj Westman, Arne Kolstad, Lone B. Pedersen, Carmen P. Montano-Almendras, Simon Husby, Catja Freiburghaus, Sara Ek, Anja Pedersen, Carsten Niemann, Riikka Räty, Peter Brown, Christian H. Geisler, Mette K. Andersen, Per Guldberg, Mats Jerkeman & Kirsten Grønbæk. (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy . Blood 130:17, pages 1903-1910.
Crossref
Antònia Obrador-Hevia, Margalida Serra-Sitjar, José Rodríguez, Lamiae Belayachi, Leyre Bento, Marta García-Recio, Jose María Sánchez, Priam Villalonga, Antonio Gutiérrez & Silvia Fernández de Mattos. (2016) Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. British Journal of Haematology 174:6, pages 899-910.
Crossref
Bryan Hambley, Paolo F. Caimi & Basem M. William. (2016) Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic Advances in Hematology 7:4, pages 196-208.
Crossref
Tadeusz Robak. (2015) Bortezomib in the treatment of mantle cell lymphoma. Future Oncology 11:20, pages 2807-2818.
Crossref
Elias Campo & Simon Rule. (2015) Mantle cell lymphoma: evolving management strategies. Blood 125:1, pages 48-55.
Crossref
Simone Ferrero & Martin Dreyling. 2015. Management of Hematological Cancer in Older People. Management of Hematological Cancer in Older People 143 168 .
M Dreyling, S Ferrero & O Hermine. (2014) How to manage mantle cell lymphoma. Leukemia 28:11, pages 2117-2130.
Crossref
Martin Dreyling. (2014) Mantle Cell Lymphoma: Biology, Clinical Presentation, and Therapeutic Approaches. American Society of Clinical Oncology Educational Book:34, pages 191-198.
Crossref
Simone Ferrero & Martin Dreyling. (2013) The current therapeutic scenario for relapsed mantle cell lymphoma. Current Opinion in Oncology 25:5, pages 452-462.
Crossref
Antonino Carbone & Anas YounesKathrin Aprile von HohenstaufenAlden MocciaEmanuele Zucca. 2013. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies 232 249 .
M. Dreyling, C. Thieblemont, A. Gallamini, L. Arcaini, E. Campo, O. Hermine, J.C. Kluin-Nelemans, M. Ladetto, S. Le Gouill, E. Iannitto, S. Pileri, J. Rodriguez, N. Schmitz, A. Wotherspoon, P. Zinzani & E. Zucca. (2013) ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of Oncology 24:4, pages 857-877.
Crossref
Eyal C. AttarJeffrey L. JohnsonPhilip C. AmreinGerard LozanskiMartha WadleighDaniel J. DeAngeloJonathan E. KolitzBayard L. PowellPeter VoorheesEunice S. WangWilliam BlumRichard M. StoneGuido MarcucciClara D. BloomfieldBarry MoserRichard A. Larson. (2013) Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. Journal of Clinical Oncology 31:7, pages 923-929.
Crossref
Christian Schmidt & Martin H. Dreyling. 2013. Lymphoma. Lymphoma 157 175 .
Shundong Cang, Nikhil Mukhi, Kemeng Wang & Delong Liu. (2012) Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology & Oncology 5:1.
Crossref
M. Witzens-Harig, G. Hess, J. Atta, M. Zaiss, G. Lenz, C. Scholz, R. Repp, M. Reiser, C. Pott, H. Pelz, P. La Rosée, H. Kirchner, P. Kiewe, U. Keller, C. Buske, A. Viardot & M. Dreyling. (2012) Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Annals of Hematology 91:11, pages 1765-1772.
Crossref
H.C. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski, M. Trneny, C.H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J.K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J.M. Zijlstra, R. Bouabdallah, P.J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Proch?zka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. Andr?W. Klapper, W. Hiddemann, M. Unterhalt & M.H. Dreyling. (2012) Treatment of Older Patients with Mantle-Cell Lymphoma. New England Journal of Medicine 367:6, pages 520-531.
Crossref
Beata Holkova & Steven Grant. (2012) Proteasome inhibitors in mantle cell lymphoma. Best Practice & Research Clinical Haematology 25:2, pages 133-141.
Crossref
Grit Hutter, Malte Rieken, Alessandro Pastore, Oliver Weigert, Yvonne Zimmermann, Marc Weinkauf, Wolfgang Hiddemann & Martin Dreyling. (2012) The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. Annals of Hematology 91:6, pages 847-856.
Crossref
Anthony R. Mato, Tatyana Feldman & André Goy. (2012) Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside. The Oncologist 17:5, pages 694-707.
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2012) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 82:1, pages 78-101.
Crossref
William Renwick. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF 225 247 .
Andre Goy & Brad Kahl. (2011) Mantle cell lymphoma: The promise of new treatment options. Critical Reviews in Oncology/Hematology 80:1, pages 69-86.
Crossref
M. Dreyling. (2011) Therapie des MantelzelllymphomsTherapy of mantle cell lymphoma. Der Onkologe 17:9, pages 806-813.
Crossref
Stéphanie Harel, Richard Delarue, Vincent Ribrag, Martin Dreyling & Olivier Hermine. (2011) Treatment of Younger Patients With Mantle Cell Lymphoma. Seminars in Hematology 48:3, pages 194-207.
Crossref
Hanneke C. Kluin-Nelemans & Jeanette K. Doorduijn. (2011) Treatment of Elderly Patients With Mantle Cell Lymphoma. Seminars in Hematology 48:3, pages 208-213.
Crossref
Qing-Fang Li, Jun Yan, Kai Zhang, Yue-Feng Yang, Feng-Jun Xiao, Chu-Tse Wu, Hua Wang & Li-Sheng Wang. (2011) Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1. Biochemical and Biophysical Research Communications 405:1, pages 31-36.
Crossref
Andre Goy. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma 107 121 .
Patrick B Johnston, RuiRong Yuan, Franco Cavalli & Thomas E Witzig. (2010) Targeted therapy in lymphoma. Journal of Hematology & Oncology 3:1.
Crossref
Jorge E. Romaguera, Luis E. Fayad, Peter McLaughlin, Barbara Pro, Alma Rodriguez, Michael Wang, Pamela Weaver, Kimberly Hartig, Larry W. Kwak, Tatyana Feldman, Judy Smith, Peggy Ford, Stuart Goldberg, Andrew Pecora & Andre Goy. (2010) Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. British Journal of Haematology 151:1, pages 47-53.
Crossref
Martin Dreyling & Wolfgang Hiddemann. (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology 2009:1, pages 542-551.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.